Variables | No.(%)/median (range) |
---|---|
Age | 60 (27–88) |
Gender | |
 Male | 1335 (79.4%) |
 Female | 346 (20.6%) |
Etiology | |
 HBV | 1039 (61.8%) |
 HCV | 279 (16.6%) |
 Alcohol | 184 (11.0%) |
 Others | 179 (10.6%) |
Cirrhosis | 1431 (85.1%) |
Tumor characteristics | |
 Number (single) | 1151 (68.5%) |
 Size, cm | 3.2 (1–20) |
 Vascular invasion | 313 (18.6%) |
 Extrahepatic metastases | 136 (8.1%) |
BCLC stage | |
 Stage A | 764 (45.4%) |
 Stage B | 495 (29.5%) |
 Stage C | 363 (21.6%) |
 Stage D | 59 (3.5%) |
Child-Pugh | |
 Child-Pugh A | 1454 (86.5%) |
 Child-Pugh B | 202 (12.0%) |
 Child-Pugh C | 25 (1.5%) |
Peripheral cell counts, 106/L | |
 Neutrophil | 3100 (630–17,500) |
 Lymphocyte | 1640 (270–7250) |
 Monocyte | 470 (60–2030) |
 Platelet | 145,000 (17,000–685,000) |
Primary treatment | |
 Resection | 407 (24.2%) |
 Liver transplantation | 51 (3.0%) |
 RFA | 138 (8.2%) |
 TACE | 710 (42.2%) |
 Sorafenib | 179 (10.7%) |
 Others | 14 (0.8%) |
 Radiotherapy | 12 (0.7%) |
 Supportive care | 171 (10.2%) |